OCULIS HOLDING AG

Oculis Holding AG reports Q2 2026 results, sees share rise after FDA green‑light for Privosegtor, reinforcing its eye‑care growth pipeline and investor confidence.

Oculis Holding AG’s clinical wins—Privosegtor FDA nod and OCS‑01 Phase 3 readouts—boost its shares 6.2 %, but a negative P/E warns investors to watch financial sustainability while the biotech targets high‑impact retinal therapies.

A recent analyst valuation of Oculis Holding AG has set the company’s intrinsic value at €36 per share, significantly higher than its current market price, suggesting potential upside for long-term investors.